glucagon receptor gene
Recently Published Documents


TOTAL DOCUMENTS

48
(FIVE YEARS 1)

H-INDEX

14
(FIVE YEARS 0)

2018 ◽  
Vol 17 ◽  
pp. 28-38 ◽  
Author(s):  
Belen Rivero-Gutierrez ◽  
April Haller ◽  
Jenna Holland ◽  
Emily Yates ◽  
Radha Khrisna ◽  
...  

2018 ◽  
Vol 103 (9) ◽  
pp. 3119-3123 ◽  
Author(s):  
Matti L Gild ◽  
Venessa Tsang ◽  
Jaswinder Samra ◽  
Roderick J Clifton-Bligh ◽  
Lyndal Tacon ◽  
...  

Abstract Context Hyperglucagonemia in the absence of glucagonomas is rare. Biallelic-inactivating mutations in the glucagon receptor gene (GCGR) cause glucagon cell hyperplasia and neoplasia (GCHN), also termed Mahvash syndrome. Here, we report the first case to our knowledge of GCHN presenting with hypercalcemia and demonstrate a unique relationship between calcium and α-cell hyperplasia. Case Description A 47-year-old man presented with severe PTH-independent hypercalcemia, 13.95 mg/dL (3.48 mmol/L). Imaging and extensive pathology tests yielded no conclusive cause. Glucagon levels >300 times the upper limit of normal were discovered. Subtotal pancreatectomy identified α-cell hyperplasia and neoplasia with metastatic disease in lymph nodes. Genomic analysis confirmed a homozygous missense variant in GCGR (Asp63Asn). This is a previously described pathologic variant and has a known association with GCHN. Conclusions Inactivating mutations of the glucagon receptor gene lead to nonfunctional hyperglucagonemia and are associated with GCHN. Homozygous or compound heterozygous GCGR mutations are associated with α-cell hyperplasia, a known precursor to pancreatic neuroendocrine tumors that can metastasize. Hypercalcemia is an unreported consequence of GCHN with an unclear mechanism.


2016 ◽  
Vol 5 (8) ◽  
pp. 731-736 ◽  
Author(s):  
Ursula H. Neumann ◽  
Jessica S.S. Ho ◽  
Majid Mojibian ◽  
Scott D. Covey ◽  
Maureen J. Charron ◽  
...  

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e456-e457
Author(s):  
A. Zanellato ◽  
P. Cohen ◽  
M. Kidd ◽  
I.M. Modlin ◽  
P. Vlavianos ◽  
...  

2009 ◽  
Vol 296 (3) ◽  
pp. E415-E421 ◽  
Author(s):  
Safina Ali ◽  
Daniel J. Drucker

Glucagon is secreted from the α-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM.


Endocrinology ◽  
2006 ◽  
Vol 147 (9) ◽  
pp. 3995-4006 ◽  
Author(s):  
Patricia M. Vuguin ◽  
Mamdouh H. Kedees ◽  
Lingguang Cui ◽  
Yelena Guz ◽  
Richard W. Gelling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document